A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension|
- Incidence of increase of iris pigmentation
- incidence of development in darkening/lengthening/thickening of eyelashes and/or pigmentation of periorbital skin
- occurrence of ocular/periorbital adverse events
- occurrence of serious adverse events.
|Study Start Date:||February 2002|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00150267
Show 74 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|